ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report)'s stock had its "buy" rating reissued by HC Wainwright in a research note issued to investors on Thursday,Benzinga reports. They presently have a $32.00 price target on the biopharmaceutical company's stock. HC Wainwright's target price would indicate a potential upside of 44.67% from the company's previous close.
Other equities analysts also recently issued reports about the company. Wall Street Zen upgraded ACADIA Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Wednesday, May 21st. BMO Capital Markets raised their price target on ACADIA Pharmaceuticals from $24.00 to $28.00 and gave the stock an "outperform" rating in a research note on Monday, May 19th. Morgan Stanley set a $24.00 price target on ACADIA Pharmaceuticals and gave the stock an "equal weight" rating in a research note on Tuesday, May 20th. Mizuho raised their price target on ACADIA Pharmaceuticals from $20.00 to $23.00 and gave the stock a "neutral" rating in a research note on Monday, May 19th. Finally, Cantor Fitzgerald upgraded ACADIA Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, June 5th. Six analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $27.88.
View Our Latest Report on ACADIA Pharmaceuticals
ACADIA Pharmaceuticals Stock Down 0.4%
Shares of ACADIA Pharmaceuticals stock traded down $0.09 on Thursday, reaching $22.12. The company's stock had a trading volume of 3,000,828 shares, compared to its average volume of 1,962,374. The company has a market capitalization of $3.70 billion, a price-to-earnings ratio of 16.15, a P/E/G ratio of 4.77 and a beta of 0.64. The firm's fifty day simple moving average is $19.60 and its two-hundred day simple moving average is $18.23. ACADIA Pharmaceuticals has a 52 week low of $13.40 and a 52 week high of $25.23.
ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last posted its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.11 EPS for the quarter, topping analysts' consensus estimates of $0.10 by $0.01. The business had revenue of $244.32 million during the quarter, compared to analyst estimates of $239.32 million. ACADIA Pharmaceuticals had a return on equity of 17.46% and a net margin of 22.97%. The company's quarterly revenue was up 18.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.10 EPS. As a group, research analysts predict that ACADIA Pharmaceuticals will post 0.7 EPS for the current year.
Insider Buying and Selling at ACADIA Pharmaceuticals
In other ACADIA Pharmaceuticals news, insider James Kihara sold 4,000 shares of the firm's stock in a transaction dated Friday, May 16th. The stock was sold at an average price of $22.50, for a total transaction of $90,000.00. Following the sale, the insider now directly owns 20,395 shares of the company's stock, valued at $458,887.50. This trade represents a 16.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Mark C. Schneyer sold 3,498 shares of the firm's stock in a transaction dated Friday, May 2nd. The shares were sold at an average price of $14.60, for a total value of $51,070.80. Following the sale, the executive vice president now directly owns 62,773 shares in the company, valued at approximately $916,485.80. This represents a 5.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 29,007 shares of company stock valued at $580,446 over the last ninety days. 28.30% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On ACADIA Pharmaceuticals
Several large investors have recently made changes to their positions in the company. Voya Investment Management LLC increased its holdings in shares of ACADIA Pharmaceuticals by 70.3% in the first quarter. Voya Investment Management LLC now owns 61,585 shares of the biopharmaceutical company's stock worth $1,023,000 after purchasing an additional 25,418 shares during the last quarter. Rhumbline Advisers increased its holdings in shares of ACADIA Pharmaceuticals by 100.9% in the first quarter. Rhumbline Advisers now owns 352,716 shares of the biopharmaceutical company's stock worth $5,859,000 after purchasing an additional 177,188 shares during the last quarter. Strs Ohio bought a new stake in shares of ACADIA Pharmaceuticals in the first quarter worth about $796,000. Intech Investment Management LLC increased its holdings in shares of ACADIA Pharmaceuticals by 45.6% in the first quarter. Intech Investment Management LLC now owns 75,872 shares of the biopharmaceutical company's stock worth $1,260,000 after purchasing an additional 23,766 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of ACADIA Pharmaceuticals by 14.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 251,056 shares of the biopharmaceutical company's stock worth $4,170,000 after purchasing an additional 31,931 shares during the last quarter. 96.71% of the stock is owned by institutional investors.
ACADIA Pharmaceuticals Company Profile
(
Get Free Report)
ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.
Featured Articles

Before you consider ACADIA Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ACADIA Pharmaceuticals wasn't on the list.
While ACADIA Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.